UK MHRA on compliance with paediatric rules
This article was originally published in Scrip
The UK regulator, theMHRA, has outlined the penalties that companies will face if they do not meet their obligations under the EU's paediatric regulation. But it has also included a "due diligence" defence so that companies that infringe the regulation can show that they took all reasonable steps to avoid doing so.
You may also be interested in...
The need to accelerate clinical trials of products for treating and preventing coronavirus has led the EU authorities to propose a more streamlined process for allowing the release of GMO-containing investigational medicinal products into the environment.
The UK’s departure from the EU imposes a number of requirements on sponsors running EU trials, but it seems that many have still not taken steps to fall into line.
As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.